Wall street sign in New York

Analyst Color

Asia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Earnings Beats

Earnings Misses

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

News

Regulations

Bonds

Broad U.S. Equity ETFs

Guidance

Eurozone

Futures

Commodities

Forex

Treasuries

Economics

Federal Reserve

Pre-Market Outlook

Markets

Analyst Ratings

ETFs

General

$BTC

AMZN

AREB

AURA

GOOG

LULU

SAGE

SLNO

U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading.



Aiming to boost U.S. manufacturing and reduce reliance on global suppliers, new auto tariffs were introduced on Wednesday, which will go into effect from April 3.

US Stocks Likely To Open Mixed: &#39;Expect Volatility. Buckle Up,&#39; Says Expert

Analysts

Price Target

Trading Ideas

Winnebago Industries Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street&#39;s Most Accurate Analysts

Muncie,-,Circa,August,2021:,Dollar,Tree,Discount,Store.,Dollar

Movers

DLTR

Dollar Tree on Wednesday announced it sold its Family Dollar segment and seemingly relieved investors sent the company&#39;s stock higher on the news. 

Dollar Tree Sells Family Dollar For $1 Billion: &#39;Truly Addition By Subtraction,&#39; Analyst Says

analyst ratings image

Kennametal Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Explore Bicycle Therapeutics analyst ratings and price targets (NASDAQ:BCYC) on Benzinga. Stay updated on expert opinions and forecasts for BCYC stock.

Bicycle Therapeutics Analyst Ratings and Price Targets | NASDAQ:BCYC | Benzinga

BICYCLE THERAPEUTICS PLC-ADR

Bicycle Therapeutics

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Why It Matters

ACHR

BCYC

CHCT

FDMT

GOOGL

TRGP

TSLA

Amazon To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Wednesday

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

ALMS

CADL

CECO

EGHT

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Biotech

Health Care

Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification.

Bicycle Therapeutics Lead Cancer Drug Combined With Merck&#39;s Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics PLC

Press Releases

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

Bicycle Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones

Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

AnaptysBio

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Chimerix

Cogent Biosciences

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Immunome

Immatics

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Kura Oncology

LENZ Therapeutics

MeiraGTx Hldgs

Organogenesis Holdings

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Replimune Group

Sage Therapeutics

Sionna Therapeutics

Tyra Biosciences

Valneva

Xencor

Needham

Citizens Capital Markets

HC Wainwright & Co.

Stephens & Co.

JMP Securities

Application error: a client-side exception has occurred (see the browser console for more information).